90 / 64
90
José Manuel Rodríguez Ferrer
Retinopatía por hidroxicloroquina
con pupila dilatada, una perimetría 10-2 de Humphrey y una ex-
ploración con al menos dos de las nuevas técnicas, preferente-
mente la TCO-SD y la ERGmf.
En pacientes sin factores de riesgo, esta exploración debe
ser repetida a los cinco años. A partir de este tiempo se realizará
anualmente.
En pacientes con factores de riesgo (tabla 1), la exploración
anterior se debe realizar anualmente.
De acuerdo con el RCO (2), aconsejamos a los médicos que
llevan a estos pacientes que en cada visita anual indaguen sobre
si tienen algún problema visual que no es corregido con lentes y
le hagan una prueba de lectura con cada ojo utilizando un texto
de 2-3 líneas con letra de tamaños 6-8 pt. Si el paciente no refiere
problemas visuales y realiza la lectura adecuadamente, el trata-
miento puede continuar y mantenerse el calendario de explora-
ciones anterior.
En caso de duda sobre la existencia de toxicidad, que no
justifique el cese de la administración de la hidroxicloroquina,
disminuir la dosis y realizar exploraciones con intervalos inferio-
res al año.
REFERENCIAS
1.
Yam JCS, Kwok AKH. Ocular toxicity of hydroxychloroquine.
Hong Kong Med J 2006; 12: 294-304.
2.
Royal College of Ophthalmologists. Hydroxychloroquine
and ocular toxicity Recommendations on Screening.
London. The College 2009.
3.
Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF. Revised
recommendations on screening for chloroquine and
hydroxychloroquine retinopathy. Ophthalmology 2011;
118: 415-422.
4.
Elder M, Rahman AMA, McLay J. Early paracentral visual
field loss in patients taking hydroxychloroquine. Arch
Ophthalmol 2006; 124: 1729-1733.
5.
Mititelu M, Wong BJ, Brenner M, Bryar PJ,Jampol L, Fawzi
AA, Progression of hydroxychloroquine toxic effects after
drug therapy cessation. New evidence from multimodal
imaging. Arch Ophthalmol 2013; 131: 1187-1197.
6.
Yoon YH, Cho KS, Hwang JJ, Lee SJ, Choi JA, Koh JY.
Induction of lysosomal dilatation, arrested autophagy,
and cell death by chloroquine in cultured ARPE-19 cells.
Invest Ophthalmol Vis Sci 2010; 51: 6030-6037.
7.
Ramsey MS, Fine BS. Chloroquine toxicity in the human
eye: Histopathologic observations by electron microscopy,
Am J Ophthalmol 1972; 73: 229-235.
8.
Bernstein HN, Ginsberg J. The pathology of chloroquine
retinopathy. Arch Ophthalmol 1964; 71: 238-45.
9.
Rosenthal RA, Kolb H, Bergsma D, Huxsoll D, Hopkins JL.
Chloroquine retinopathy in the rhesus monkey. Invest
Ophthalmol Vis Sci 1978; 17: 1158-75.
10. Korah S, Kuriakose T. Optical coherence tomography in a
patient with chloroquine-induced maculopathy. Indian J
Ophthalmol 2008; 56: 511-513.
11. Marmor MF, Carr RE, Easterbook M, Farjo AA, William
F, Mieler WF. Recommendations on screening for
chloroquine
and
hydroxychloroquine
retinopathy.
Ophthalmology 2002; 109:1377-1382.
12. Levy GD, Munz SJ, Paschal J, Cohen HB, Pince KJ, Peterson
T. Incidence of hydroxychloroquine retinopathy in 1,207
patients in a large multicenter outpatient practice. Arthritis
Rheum 1997; 40: 1482-1486.
13. Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou
A, Kostopoulos C et al. The incidence of irreversible retinal
toxicity in patients treated with hydroxychloroquine: a
reappraisal. Ophthalmology 2003; 110: 1321-1326.
14. Browning DJ. Impact of the revised American Academy of
Ophthalmology guidelines regarding hydroxychloroquine
screening on actual practice. American Journal of
Ophthalmology 2013; 155: 418-428.
15. Mackenzie AH. Dose refinements in long-term therapy of
rheumatoid arthritis with antimalarials. Am J Med 1983; 75:
40-45.
16. Easterbrook M. Screening for antimalarial toxicity: current
concepts. Can J Ophthalmol 2002; 37: 325-328.
17. Marmor MF. Comparison of screening procedures in
hydroxychloroquine toxicity. Arch Ophthalmol 2012; 130:
461-469.
18. Johnson MW, Vine AK. Hydroxychloroquine therapy in
massive total doses without retinal toxicity. Am J Ophthalmol
1987; 104: 139-144.
19. Wolfe F, Marmor MF. Rates and predictors of
hydroxychloroquine retinal toxicity in patients with
rheumatoid arthritis and systemic lupus erythematosus.
Arthritis Care Res 2010; 62: 775-784.
20. Bernstein HN. Ocular safety of hydroxychloroquine. Ann
Ophthalmol 1991; 23: 292-296.
21. Tailor R, Elaraoud I, Good P, Hope-Ross M, Scott RAH. A Case
of Severe Hydroxychloroquine-Induced Retinal Toxicity in a
Patient with Recent Onset of Renal Impairment: A Review
of the Literature on the Use of Hydroxychloroquine in Renal
Impairment. Case Reports in Ophthalmological Medicine
2012; Article ID 182747, 3 pages doi:10.1155/2012/182747.
22. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity
despite normal dose therapy. Ann Ophthalmol 1993; 25: 385-
388.
23. Farrell DF. Retinal toxicity to antimalarial drugs: chloroquine
and hydroxychloroquine: a neurophysiologic study. Clinical
Ophthalmology 2012; 6: 377-383.
24. Portnoy JZ, Callen JP. Ophthalmologic aspects of chloroquine
and hydroxychloroquine therapy. Int J Dermatol 1983; 22:273-
278.
25. Vu BL, Easterbrook M, Hovis JK. Detection of color vision
defects in chloroquine retinopathy. Ophthalmology 1999;
106: 1799-1804.
26. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal
toxicity associated with hydroxychloroquine and chloroquine:
risk factors, screening, and progression despite cessation of
therapy. Arch Ophthalmol 2011; 129: 30-39.
27. ReedH, KarlinskyW. Delayed onset of chloroquine retinopathy.
Can Med Assoc J 1967; 97: 1408-1411.
28. Bernstein HN. Ophthalmologic considerations and testing in
patients receiving long-term antimalarial therapy. Am J Med
1983; 75: 25-34.
29. Herman K, Leys A, Spileers W. (Hydroxyl)-chloroquine retinal
toxicity: two case reports and safety guidelines. Bull Soc Belge